02 9487 9111
The University of Sydney Avondale College of Higher Education
 

Sydney Adventist Hospital
« View pages

Clinical Specialties - Cancer

Breast Cancer Clinical Trials

METRIC

A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer

http://clinicaltrials.gov/ct2/show/NCT01997333


MONARCH 3

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting

https://www.clinicaltrials.gov/ct2/show/NCT02246621?term=I3Y-MC-JPBM&rank=1


SOLAR-1

A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment

https://www.clinicaltrials.gov/ct2/show/NCT02437318?term=placebo+controlled+study+of+alpelisib+in+combination+with+fulvestrant+for+men+and+postmenopausal+women+with+hormone+receptor+positive&rank=1


PUMA 6201 - Recruiting

An Open-Label Study to Characterize the Incidence and Severity of Diarrhoea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Intensive Loperamide Prophylaxis

https://clinicaltrials.gov/ct2/show/NCT02400476


CONTESSA - Recruiting

A multinational, multicenter, randomized, open-label, parallel group Phase 3 study to compare the efficacy of tesetaxel plus a reduced dose of capecitabine versus the approved dose of capecitabine alone in patients with HER2 negative, HR positive MBC previously treated with a taxane in the neoadjuvant or adjuvant setting

https://www.clinicaltrials.gov/ct2/show/NCT03326674?term=contessa&rank=1


WINPRO - Recruiting

An open-label, randomized, window of opportunity study between diagnosis and definite surgery, to assess the effect of antiestrogen therapies, alone and in combination with microionized progesterone (prometrium) in patients with newly diagnosed ER+PR+ breast cancer

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371406&isReview=true


AZTEC - Recruiting

A Randomised Phase II Trial Comparing the Efficacy of Single-fraction or Multi-fraction SABR (Stereotactic Ablative Body Radiotherapy) With AteZolizumab in Patients With Advanced Triple Negative Breast Cancer

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=6987&isClinicalTrial=True


IMpassion030 - Pending

A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer

https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=7058&isClinicalTrial=True


NATALEE - Recruiting

A trial to evaluate the efficacy and safety of Ribociclib with Endocrine therapy as adjuvant treatment in patients with HR=/HER2-ve early breast cancer

Link will be available soon.

Back to Top

Sydney Adventist Hospital Clinical Specialties and Services